Prodrug activation by Cryptosporidium thymidine kinase

Area of Science:

• Parasitology
• Biochemistry
• Drug Discovery

Background:

• Cryptosporidium spp. cause severe gastrointestinal illness, particularly in immunocompromised individuals.
• Existing antiparasitic drugs are largely ineffective against these protozoan parasites.
• Cryptosporidium lacks de novo pyrimidine biosynthesis, relying on salvage pathways for essential molecules like dTMP.

Purpose of the Study:

• To express and characterize thymidine kinase (TK) from Cryptosporidium parvum (CpTK).
• To investigate CpTK as a potential drug target for treating cryptosporidiosis.

Main Methods:

• Expression and biochemical characterization of C. parvum thymidine kinase (CpTK).
• Enzyme kinetics studies with various substrates and activators.
• In vitro and in vivo testing of CpTK-activated pro-drugs against C. parvum infection.

Main Results:

• CpTK forms a stable trimer, distinct from other TKs.
• CpTK exhibits substrate specificity, with a high Km for thymidine.
• Trifluoromethyl thymidine and 5-fluorodeoxyuridine are effective substrates that inhibit parasite growth.
• Trifluorothymidine demonstrated efficacy in a mouse model of cryptosporidiosis.

Conclusions:

• CpTK is a viable target for developing novel antiparasitic therapies.
• CpTK-activated pro-drugs show promise for treating cryptosporidiosis.
• Further research into Cryptosporidium's nucleoside metabolism is warranted.